12:00 AM
 | 
Mar 08, 2010
 |  BioCentury  |  Finance

Ebb & Flow

Adventrx Pharmaceuticals Inc. (NYSE-A:ANX) fell $0.09 (30%) to $0.20 on Monday after FDA refused to file an NDA for ANX-530 to treat non-small cell lung cancer (NSCLC) because of a problem with CMC data from the intended commercial manufacturing site. The stock was off $0.07 (24%) to $0.22 for the week.

Amgen Inc. (NASDAQ:AMGN) gained $0.63 to $57.24 last week after the U.K.'s NICE issued a preliminary appraisal for five drugs to treat rheumatoid arthritis after failure on a TNF inhibitor. NICE reiterated recommendations in favor of MabThera rituximab, a mAb against CD20 from Roche (SIX:ROG; OTCQX:RHHBY); and against use of Orencia abatacept, a CTLA-4-Ig fusion protein from Bristol-Myers Squibb Co. (NYSE:BMY).

As part of the appraisal, the NICE committee recommended against TNF inhibitors Enbrel etanercep from Amgen and Pfizer Inc. (NYSE:PFE), Remicade infliximab from Johnson & Johnson (NYSE:JNJ) and Merck & Co. Inc. (NYSE:MRK), and Humira adalimumab from Abbott Laboratories (NYSE:ABT) to treat RA after the failure of a previous anti-TNF drug (see B9).

Separately, academic researchers published data in the Journal of the American Medical Association showing that greater use of erythropoiesis-stimulating agents (ESAs) and iron was associated with a decreased risk of mortality. Amgen markets ESAs Aranesp darbepoetin alfa and Epogen epoetin alfa (see B13).

Biodel Inc. (NASDAQ:BIOD) gained $0.23 to $4.22 last week after FDA accepted for review an NDA for VIAject injectable recombinant human insulin to treat Type I and Type II diabetes.

Celgene Corp. (NASDAQ:CELG) was up $2.39...

Read the full 1297 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >